Burrill Institutional Research "SRPT is an Undervalued Opportunity " Target $ 54
The Street Insider 11/26
Burrill Starts Sarepta (SRPT) at Market Outperform; Sees Plenty of Upside in DMD Space
Burrill Institutional Research started coverage on Sarepta Therapeutics (Nasdaq: SRPT) at Market Outperform establishing a $54 price target in the process.
Analyst/managing director Reni Benjamin commented, "To date, the company has demonstrated both safety and preliminary efficacy in Phase 1 and Phase 2 trials with patients amenable to Exon 51 therapy in Duchenne’s Muscular Dystrophy (DMD). Given the final encouraging results from the 201/202 Phase 2 study, we believe shares are poised to move higher. If successful, we believe Sarepta’s directed alternative splicing technology has the potential to revitalize the RNA therapeutics space and address multiple multi-billion dollar orphan disease markets. In our opinion, the company represents an undervalued opportunity with multiple near-term drivers poised to create shareholder value in 2013."